New cancer drug shows promise in early trial for Tough-to-Treat tumors
NCT ID NCT04892342
Summary
This study tested a new drug called ESG401 in people with advanced solid tumors that had spread or couldn't be removed by surgery. The main goals were to find a safe dose and see if the drug could shrink tumors in cancers like breast, lung, colorectal, and ovarian. The trial involved 156 participants who had already tried other treatments that didn't work well or caused too many side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS, COLORECTAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310003, China
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300060, China
Conditions
Explore the condition pages connected to this study.